What Biocon does

Biocon Limited is an India-headquartered, publicly listed biopharmaceutical company (BSE: 532523, NSE: BIOCON) founded in 1978 by Kiran Mazumdar-Shaw and now operating across more than 120 countries with over 10,000 employees. It develops, manufactures and commercializes a portfolio spanning biosimilars (60% of group revenue), generic APIs and formulations, novel biologics, and contract research services through its listed subsidiary Syngene International. Core therapeutic areas are diabetes/insulin, oncology, immunology/autoimmune, and increasingly metabolic/obesity (GLP-1), serving government health systems, hospital networks, payers and ultimately patients who need affordable access to complex biologics.

The company's technical foundation rests on proprietary bioprocess platforms — most notably the Pichia pastoris yeast expression system for recombinant insulin and biologics, and PlaFractor solid-state fermentation technology for immunosuppressants — combined with what it describes as Asia's largest insulin manufacturing facility in Johor, Malaysia, plus a new EMA-approved fill-finish line. Its product portfolio includes Semglee (the first FDA-approved interchangeable biosimilar insulin glargine), Yesafili (aflibercept biosimilar with interchangeable designation), CANMAb and KRABEVA (oncology biosimilars), the world's first biosimilar trastuzumab, India's first indigenous novel monoclonal antibody Nimotuzumab, generic immunosuppressants (MMF, tacrolimus, sirolimus, everolimus), and fermentation-derived statins. Novel pipeline assets include Insulin Tregopil (oral insulin partnered with JDRF) and Itolizumab (anti-CD6 antibody partnered with Equillium).

Biocon makes money through a multi-channel go-to-market model: direct field sales and commercialization in developed markets (U.S., Europe, Canada, Japan, Australia, New Zealand) following the January 2026 acquisition of Viatris' global biosimilars business for up to USD 3.335 billion; government and institutional tenders in emerging markets (notably Malaysia's Ministry of Health via Duopharma Biotech); and a 10-year commercial collaboration with Eris Lifesciences covering Metabolics, Oncology, Nephrology, Dermatology and Critical Care products in India. Pricing follows unit/wholesale-acquisition-cost models for biologics (Semglee launched at the lowest WAC for any long-acting insulin glargine in the U.S.) and value-based pricing for novel biologics, with biosimilars typically priced 15–35% below reference products. Distribution listings on major U.S. PBM formularies and India-domestic channels round out a B2B/B2G revenue architecture that delivered FY26 operating revenue of Rs 16,927 crore.

Name

Biocon

Legal name

Biocon Limited

Website

http://www.biocon.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Biocon is an India-based biopharmaceutical company that develops, manufactures and commercializes biosimilars (60% of revenue), generic APIs, and novel biologics across 120+ countries. It serves government health systems, hospital networks and payers via its Pichia pastoris yeast platform and Asia's largest insulin facility in Johor, Malaysia.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Biosimilars & Generics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Biosimilar Commercialization & Market Access (pricing, tendering, interchangeability, distribution) (HLAAAHAL)

akta.pro secondary industries

Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ), Biologics & Biosimilars Distributors (HLAIAJAH), Insulin & Analog Biosimilars (HLAAAHAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Biosimilar manufacturing
• Insulin production
• Generic pharmaceuticals
• Contract research services
• Biologic drug development

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Biosimilars: Revenue from biosimilar products including insulin glargine (Semglee), trastuzumab, bevacizumab, aflibercept (Yesafili), denosumab, and others. Accounts for 60% of group revenue. Commercialized in U.S., Europe, Australia, Canada, Japan, and emerging markets. FY26 revenue from biosimilars was Rs 10,431 crore with 16% YoY growth and 40% EBITDA increase.
2. Generics (API and Generic Formulations): Active Pharmaceutical Ingredients (APIs) including statins, immunosuppressants (MMF, Tacrolimus, Sirolimus, Everolimus), and generic formulations sold in India, U.S., and Europe.
3. Research Services (Syngene): Contract research and manufacturing services through subsidiary Syngene International (CRDMO model), though Syngene has faced turnaround challenges.
4. Novel Biologics: Pipeline of novel biologics and immunotherapy assets including Itolizumab and Insulin Tregopil, some partnered with JDRF and Equillium.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Biocon develops, manufactures, and commercializes a portfolio of biosimilars (insulins, oncology mAbs, immunology), generic APIs and formulations (statins, immunosuppressants), novel biologics, and contract research/manufacturing services (via subsidiary Syngene). Products are commercialized in 120+ countries targeting diabetes, oncology, immunology, and autoimmune diseases, with vertically integrated R&D, manufacturing, and global commercialization.

Product overview

Biocon is an innovation-led global biopharmaceutical company with a unified structure spanning biosimilars, generics, novel biologics, and research services. The core biosimilars portfolio includes Semglee (insulin glargine - first interchangeable US biosimilar), Yesafili (aflibercept), CANMAb (trastuzumab), and KRABEVA (bevacizumab). Novel biologics include Nimotuzumab (BIOMAb EGFR) and Itolizumab. Generics comprise recombinant human insulin (Insupen), immunosuppressants (MMF, Tacrolimus), and statins. Research services are delivered through subsidiary Syngene. Biocon Biologics, now a wholly-owned subsidiary, manages the integrated biosimilars business valued at USD 5.5 billion.

Differentiator

Problem solved

Functional benefit

Brands

• Semglee: Insulin glargine biosimilar; first interchangeable biosimilar in US for diabetes treatment
• CANMAb
• KRABEVA
• BIOMAb EGFR
• Insugen
• Itolizumab
• Yesafili

Products and services

• Semglee (insulin glargine-yfgn) FDA-approved interchangeable biosimilar insulin glargine for diabetes treatment, allowing pharmacy-level substitution without prescriber intervention. Launched at the lowest wholesale acquisition cost (WAC) for any long-acting insulin glargine in the U.S. market.
• Yesafili (aflibercept-jbvf) Interchangeable biosimilar of aflibercept (EYLEA reference product) for diabetic macular edema and related ophthalmologic indications, supported by Phase III INSIGHT trial data.
• CANMAb (Trastuzumab biosimilar) Biosimilar trastuzumab for HER2-positive metastatic breast cancer, providing affordable access to a biologic oncology therapy.
• KRABEVA (Bevacizumab biosimilar) Pan-cancer biosimilar bevacizumab for metastatic colorectal cancer and other lung, kidney, cervical, ovarian, and brain cancers, featuring a unique Qual-Check mechanism for quality assurance.
• Yesintek (ustekinumab biosimilar) Biosimilar ustekinumab for plaque psoriasis and other autoimmune indications. Captured nearly one-fifth of the U.S. plaque psoriasis market within its commercial period.
• BIOMAb EGFR (Nimotuzumab) Novel anti-EGFR monoclonal antibody (Nimotuzumab) for head and neck cancer treatment, marking India's first indigenously developed novel monoclonal antibody.
• Itolizumab (ALZUMAb-L)
• Insugen (Recombinant Human Insulin / Insupen) India's first indigenous recombinant human insulin product for diabetes management, manufactured using Biocon's proprietary Pichia pastoris yeast expression platform.
• Basalog (Insulin Glargine, India) Biosimilar insulin glargine marketed in India for diabetes management, expanding Biocon's domestic insulin portfolio.
• GLP-1 Portfolio (Liraglutide)
• Micafungin for Injection Antifungal injection (micafungin) approved by Health Canada in 50mg and 100mg strengths for treatment of systemic Candida infections and prophylaxis in hematopoietic stem cell transplant patients.
• Syngene Contract Research and Manufacturing Services (CRDMO)
• Generic Immunosuppressants (MMF, Tacrolimus, MPA, Sirolimus, Everolimus)
• Statins (Lovastatin, fermentation-derived) Fermentation-derived statins for reducing blood cholesterol and preventing heart disease.

Quantifiable outcome

• Semglee (insulin glargine) launched at lowest WAC for any long-acting insulin glargine in U.S. market, enabling significant cost savings versus Lantus reference product
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Biocon Biologics LimitedcoreStrategic or Co-development Partner · 6 December 2025Biocon integrated Biocon Biologics Limited as a wholly owned subsidiary effective June 29, 2026, completing a restructuring process projected through March 31, 2026. Biocon Biologics valued at USD 5.5 billion. The integration unifies biosimilars and generics businesses into one biopharma enterprise.
• Viatris Inc. (formerly Mylan)coreStrategic or Co-development Partner · 27 February 2022Biocon Biologics acquired Viatris' global biosimilars business for up to USD 3.335 billion (USD 2 billion cash + USD 1 billion CCPS + USD 335 million deferred). Transaction closed in January 2026. Brought Viatris' commercialization infrastructure in developed markets (U.S., Europe, Canada, Japan, Australia, New Zealand) under BBL ownership. Viatris received 12.9% equity stake in BBL via CCPS. Mylan subsequently exited entire 5.64% stake in Biocon Limited via Rs 3,481 crore block deal in July 2026.
• Serum Institute Life Sciences (SILS)coreStrategic or Co-development Partner · 1 September 2021Strategic alliance for vaccines and biologics. SILS invested USD 300 million total in Biocon Biologics (USD 150 million in November 2022 + USD 150 million converted from loan). BBL receives access to 100 million doses of vaccines annually and distribution rights to Serum's vaccine portfolio for global markets. Aligned with 13th Malaysia Plan and New Industrial Master Plan 2030.
• Duopharma Biotech Berhad (Malaysia)coreChannel Partner/ Reseller/ DistributorLong-standing partnership since 2016. Duopharma Biotech Berhad secured insulin supply contracts from Malaysia's Ministry of Health worth over MYR 225 million annually. Biocon's Malaysian subsidiary Biocon Sdn. Bhd. supplies recombinant human insulin, insulin glargine, and insulin aspart. Partnership has delivered over 120 million insulin cartridges to 450,000+ patients in Malaysia's public healthcare system. Johor manufacturing facility is the largest insulin plant in Asia.
• Eris LifesciencescoreChannel Partner/ Reseller/ DistributorLong-term commercial collaboration for branded formulations in India. Transaction value INR 12,420 million (3.4x revenue multiple, 18x EBITDA multiple). Covers Metabolics, Oncology, Nephrology, Dermatology, and Critical Care products. 10-year supply agreement. Over 430 employees transitioned to Eris. Initial collaboration for Nephrology and Dermatology announced December 2023; expanded to full portfolio in March 2024.
• JDRFminorStrategic or Co-development PartnerPartnership with JDRF (type 1 diabetes research and advocacy organization) to support global multiple ascending dose study with novel oral insulin drug candidate Insulin Tregopil in people with type 1 diabetes.
• EquilliumminorStrategic or Co-development PartnerPartnership for development of Itolizumab (anti-CD6 antibody), including COVID-19 applications. Equillium provides additional development resources and U.S. market expertise for Itolizumab.
• Adagio TherapeuticsminorStrategic or Co-development PartnerPartnership for ADG20, a novel antibody therapy for COVID-19 prevention and treatment. Entails manufacturing and commercialization rights in emerging markets including India. Single-dose intramuscular injection development.

Scale indicators13 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Celltrion: South Korean biosimilars company with leading global biosimilar portfolio including Remsima (infliximab), Herzuma (trastuzumab), and Truxima (rituximab). Direct competitor to Biocon in biosimilars markets globally, particularly in oncology and immunology.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars in immunology, oncology, and ophthalmology. Direct competitor to Biocon with approved biosimilars including Renflexis, Imraldi, and Byooviz.

Broad incumbents

• Dr. Reddy's Laboratories: Indian multinational pharmaceutical company with biosimilars, generics, and APIs. Comparable to Biocon as a fellow Indian pharma company with global biosimilars ambitions and a similar therapeutic focus on oncology and immunology.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company with global generics and specialty portfolio. Comparable to Biocon as a major Indian pharma with biosimilars initiatives and broad therapeutic coverage including immunology through its Taro subsidiary.
• Amgen: Major US biopharmaceutical company that is both a developer of originator biologics and a participant in biosimilars through Amjevita (adalimumab biosimilar). Comparable to Biocon for its biologics manufacturing capabilities and biosimilar commercial launches.
• Novo Nordisk: Global leader in insulin and GLP-1 therapies (Ozempic, Wegovy). Direct competitor to Biocon in insulin and emerging competitor in GLP-1, with dominant share in India diabetes market through products like Awiqli.
• Eli Lilly: Major pharmaceutical company with significant diabetes (Trulicity, Mounjaro) and immunology portfolio. Comparable to Biocon as a biologics manufacturer with competing GLP-1 offerings and originator of insulin products.
• Roche Holding: Swiss pharmaceutical company that is the originator of key biologics Biocon biosimilars (trastuzumab/Herceptin, bevacizumab/Avastin, rituximab/Rituxan). Comparable as the reference product manufacturer whose patents Biocon's biosimilars compete against.
• Pfizer: Global pharmaceutical company with biosimilars portfolio including Inflectra (infliximab), Nivestym (filgrastim), and Trazimera (trastuzumab). Comparable to Biocon as a major competitor in biosimilars commercialization, particularly in oncology.

Regional players

• Lupin Limited: Indian pharmaceutical company with focus on generics, APIs, and biosimilars. Comparable to Biocon as a fellow Indian pharma with significant US generics presence and emerging biosimilars portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biocon
• Xx.com/bioconlimited
• Facebookfacebook.com/bioconlimited

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds5 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocon